近幾年慢性C 型肝炎(hepatitis C virus, HCV) 的治療用藥迅速發展, 注射型的干擾素時代已經
過去, 取而代之的是全口服劑型的直接抗病毒藥品(direct-acting antivirals, DAAs) …

The year 2011 marks the dawn of the new era of direct-acting antivirals for hepatitis C. For
the first time since 1998, the US Food and Drug Administration approved two new antiviral …

Most direct‐acting antivirals (DAAs) that are being developed as therapy against hepatitis C
virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter …

Hepatitis C virus (HCV) infection is one of the primary causes of liver cirrhosis,
hepatocellular carcinoma (HCC), and liver transplantation (LT). The rate of HCV infection is …

The successful development of direct-acting antivirals (DAA) represents a breakthrough in
the treatment of hepatitis C virus (HCV) infection. Pegylated interferon alpha and ribavirin …

Background Patients with inherited blood disorders (IBLD) have a high risk of hepatitis C
virus (HCV) infection. The aim of this work was to assess the efficacy and safety of HCV …

The data on direct‐acting antivirals (DAAs) in chronic hepatitis C (CHC) patients in southern
China with multiple genotypes circulating are limited. This study aims to evaluate the efficacy …

摘要C 型肝炎病毒感染一直是全球公共衛生上的重要課題. 慢性C 型肝炎的治療在近年來已經有
了長足的進步, 亞太地區在這個研究領域上也有許多深入的研究與新的發現. 本文針對這個主題 …

Background/purpose Treatment of chronic hepatitis C (CHC) has entered a new era since
the introduction of direct-acting antiviral agents (DAAs). Numerous clinical trials have shown …

Objective New potent direct-acting antiviral (DAA) regimens against hepatitis C virus have
been approved in recent years. However, information about the rate of adverse events (AEs) …